FEops elects Rob Michiels as Chairman
Former CardiAQ Valve Technologies CEO and CoreValve COO says FEops' "predictive procedure-planning platform" may be crucial to the ultimate-outcome success of transcatheter-based valve therapies
"Certainly, Rob Michiels is one of the most experienced, most successful executives in the cardiovascular industry." Matthieu De Beule, PhD, CEO, FEops
Ghent, Belgium: 16 September 2016 - FEops, which is developing "future-generation planning technology for transcatheter valve therapies", today announced that it has elected Rob Michiels to serve as Chairman of the Board of Directors, effectively immediately. Until September 2015, Michiels was Chief Executive Officer at CardiAQ Valve Technologies, the Transcatheter Mitral Valve Replacement (TMVR) company, which was acquired by Edwards Lifesciences.
More info on FEops' website.
Next > ReActiv8-A Clinical Trial – Sustained Performance at One Year
Previous > Nexstim Plc agrees the next steps of the NBT stroke de novo submission with the FDA